NEW YORK, August 4, 2017 /PRNewswire/ --
If you want a Stock Review on ELGX, ZBH, PODD, or BCR then come over to
Irvine, California headquartered Endologix Inc.'s stock finished Thursday's session 10.49% lower at $4.35. A total volume of 2.64 million shares was traded, which was above their three months average volume of 1.32 million shares. Shares of the Company are trading below their 50-day moving average by 11.04%. Moreover, shares of Endologix, which develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the US and internationally, have a Relative Strength Index (RSI) of 34.90.
On August 02nd, 2017, Endologix announced financial results for Q2 ended June 30th, 2017. Global revenue for Q2 2017 was $48.6 million, gross profit was $32.2 million, total operating expenses were $40.1 million, and net loss was $16.3 million. Total cash, cash equivalents, restricted cash, and marketable securities were $94.5 million as of June 30th, 2017. Your complete research report on ELGX can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=ELGX
Shares in Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc. declined 0.45%, ending yesterday's session at $117.16. A total volume of 2.04 million shares was traded, which was above their three months average volume of 1.48 million shares. The stock has gained 0.27% in the previous three months and 13.53% on an YTD basis. The Company's shares are trading 0.16% above their 200-day moving average. Moreover, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, Middle-East, Africa, and Asia/Pacific, have an RSI of 22.12.
On July 11th, 2017, Zimmer Biomet announced that David C. Dvorak has stepped down as President and CEO and member of the Board of Directors, effective that day. The Board has appointed Daniel P. Florin, Senior Vice President and CFO, to serve in the additional role of Interim CEO and a member of the Board of Directors until a permanent successor has been named.
On July 14th, 2017, research firm Bank of America/ Merrill reiterated its 'Buy' rating on the Company's stock with a target price of $158 a share. A free report on ZBH is just a click away at: http://dailystocktracker.com/registration/?symbol=ZBH
On Thursday, Billerica, Massachusetts headquartered Insulet Corp.'s stock saw a slight decline of 0.54%, to close the day at $50.09. A total volume of 343,064 shares was traded. The Company's shares have surged 22.02% in the previous three months and 32.94% on an YTD basis. The stock is trading 4.56% and 18.28% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Insulet, which develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the US and internationally, have an RSI of 51.13.
On July 17th, 2017, research firm BTIG Research downgraded the Company's stock rating from 'Buy' to 'Neutral'.
On August 01st, 2017, Insulet announced that management will present at three, upcoming, investor conferences in New York: the 2017 Wedbush PacGrow Healthcare Conference on August 15th, 2017, at 9:10 a.m. ET; the Baird 2017 Global Healthcare Conference on September 06th, 2017, at 8:30 a.m. ET; and the Morgan Stanley Global Healthcare Conference on September 11th, 2017, at 4:50 p.m. ET. Sign up for your complimentary research report on PODD at: http://dailystocktracker.com/registration/?symbol=PODD
Shares in Murray Hill, New Jersey headquartered C.R. Bard Inc. ended the day 0.98% lower at $319.37. A total volume of 494,419 shares was traded. The stock has gained 0.53% in the last one month, 4.17% in the previous three months, and 42.16% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 1.00% and 22.43%, respectively. Furthermore, shares of C.R. Bard, which together with its subsidiaries, designs, manufactures, packages, distributes, and sells medical, surgical, diagnostic, and patient care devices worldwide, have an RSI of 50.60.
On July 27th, 2017, C.R. Bard reported Q2 2017 financial results. Net sales for the quarter were $979.7 million, net sales in the US were $660.2 million, net income was $139.7 million, and diluted earnings per share (EPS) were $1.86. In conjunction with the Q2 2017 results, the Company is maintaining its 2017 financial revenue guidance, and is increasing its adjusted diluted EPS guidance. Register for free on DailyStockTracker.com and download the latest research report on BCR at: http://dailystocktracker.com/registration/?symbol=BCR
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected] . Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
A prosthetic heart valve is an artificial device surgically implanted into the heart to replace a ...
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...View All